Instrument Inactif

Autres langues NICOX Swiss Exchange

Actions

OXCOX

FR0000074130

Produits pharmaceutiques

Autres langues

16/09	Data on Nicox's NCX 470 to be presented at AAOpt Annual Meeting 2026
11/09	Chinese Regulator Accepts Nicox's Glaucoma Drug Application for Review
11/09	Nicox S.A. Announces Acceptance Of NCX 470 NDA For Review In China
11/09	Nicox Announces NCX 470 NDA in China Accepted for Review
02/09	Nicox Announces Extension of Cash Runway
02/09	Nicox S.A. Announces Appointment of Doug Hubatsch as Chief Scientific Advisor
27/08	US FDA to Complete Nicox's Glaucoma Drug Review by April 2027
27/08	Nicox Announces April 2027 PDUFA Date for NCX 470 in Glaucoma
27/08	Nicox S.A. Announces U.S. Food and Drug Administration Accepts the New Drug Application for NCX 470
10/08	Nicox Sa and Ocumension Therapeutics Submit Ncx 470 New Drug Application in China
10/08	Nicox Partner Files China Drug Application for NCX 470 Eye Drop
10/08	Nicox Announces NCX 470 NDA Submission in China by Partner Ocumension
01/07	Nicox Submits NCX 470 New Drug Application In The United States
01/07	Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment
23/06	Nicox Bags EUR6 Million Shareholder Loan
23/06	Nicox and Vester Finance Sign Shareholder Loan Agreement to Support Strategic Activities for the Company
18/06	Nicox Announces Positive Pre-Submission Regulatory Feedback in China Supporting NDA Filing for NCX 470
18/06	Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470
08/06	Reminder: Nicox June 2024 Warrants will expire June 19, 2026
03/06	Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 24, 2026 and appointment of an ad hoc representative
30/04	Nicox Provides Full Year 2025 Financial Results and Corporate Update
30/04	Nicox S.A. Reports Earnings Results for the Full Year Ended December 31, 2025
20/04	Reminder: Last Exercise Day for Nicox June 2024 Warrants is June 19, 2026
24/02	Nicox SA Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting
24/02	Nicox Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting